174 related articles for article (PubMed ID: 12217749)
21. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.
Gately S; Twardowski P; Stack MS; Patrick M; Boggio L; Cundiff DL; Schnaper HW; Madison L; Volpert O; Bouck N; Enghild J; Kwaan HC; Soff GA
Cancer Res; 1996 Nov; 56(21):4887-90. PubMed ID: 8895739
[TBL] [Abstract][Full Text] [Related]
22. Angiostatin binds ATP synthase on the surface of human endothelial cells.
Moser TL; Stack MS; Asplin I; Enghild JJ; Højrup P; Everitt L; Hubchak S; Schnaper HW; Pizzo SV
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2811-6. PubMed ID: 10077593
[TBL] [Abstract][Full Text] [Related]
23. p22 is a novel plasminogen fragment with antiangiogenic activity.
Kwon M; Yoon CS; Fitzpatrick S; Kassam G; Graham KS; Young MK; Waisman DM
Biochemistry; 2001 Nov; 40(44):13246-53. PubMed ID: 11683633
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor fails to acutely modulate endothelial permeability during early angiogenesis in the chick chorioallantoic membrane.
DeFouw LM; DeFouw DO
Microvasc Res; 2000 Nov; 60(3):212-21. PubMed ID: 11078637
[TBL] [Abstract][Full Text] [Related]
25. Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis.
Ribatti D; Nico B; Morbidelli L; Donnini S; Ziche M; Vacca A; Roncali L; Presta M
J Vasc Res; 2001; 38(4):389-97. PubMed ID: 11455210
[TBL] [Abstract][Full Text] [Related]
26. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression.
Sun X; Kanwar JR; Leung E; Lehnert K; Wang D; Krissansen GW
Cancer Gene Ther; 2001 Oct; 8(10):719-27. PubMed ID: 11687895
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor-beta 1 inhibits generation of angiostatin by human pancreatic cancer cells.
O'Mahony CA; Albo D; Tuszynski GP; Berger DH
Surgery; 1998 Aug; 124(2):388-93. PubMed ID: 9706163
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
29. Different inhibitors of plasmin differentially affect angiostatin production and angiogenesis.
Hatziapostolou M; Katsoris P; Papadimitriou E
Eur J Pharmacol; 2003 Jan; 460(1):1-8. PubMed ID: 12535853
[TBL] [Abstract][Full Text] [Related]
30. Anti-angiogenic activity of the purine analog 6-thioguanine.
Presta M; Belleri M; Vacca A; Ribatti D
Leukemia; 2002 Aug; 16(8):1490-9. PubMed ID: 12145690
[TBL] [Abstract][Full Text] [Related]
31. Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells.
Binda MM; Matar P; González AD; Rozados VR; Gervasoni SI; Scharovsky OG; Bonfil RD
Int J Cancer; 2002 Jul; 100(1):14-21. PubMed ID: 12115581
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
33. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells.
Redlitz A; Daum G; Sage EH
J Vasc Res; 1999; 36(1):28-34. PubMed ID: 10050071
[TBL] [Abstract][Full Text] [Related]
34. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
O'Reilly MS
EXS; 1997; 79():273-94. PubMed ID: 9002223
[TBL] [Abstract][Full Text] [Related]
35. Angiostatin up-regulation in gastric cancer cell SGC7901 inhibits tumorigenesis in nude mice.
Wu J; Shi YQ; Wu KC; Zhang DX; Yang JH; Fan DM
World J Gastroenterol; 2003 Jan; 9(1):59-64. PubMed ID: 12508352
[TBL] [Abstract][Full Text] [Related]
36. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
Sasaki T; Larsson H; Kreuger J; Salmivirta M; Claesson-Welsh L; Lindahl U; Hohenester E; Timpl R
EMBO J; 1999 Nov; 18(22):6240-8. PubMed ID: 10562536
[TBL] [Abstract][Full Text] [Related]
37. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3.
Anand-Apte B; Pepper MS; Voest E; Montesano R; Olsen B; Murphy G; Apte SS; Zetter B
Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):817-23. PubMed ID: 9112976
[TBL] [Abstract][Full Text] [Related]
39. Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma.
Gorrin-Rivas MJ; Arii S; Mori A; Takeda Y; Mizumoto M; Furutani M; Imamura M
Ann Surg; 2000 Jan; 231(1):67-73. PubMed ID: 10636104
[TBL] [Abstract][Full Text] [Related]
40. Angiostatin expression in non-small cell lung cancer.
Volm M; Mattern J; Koomägi R
Clin Cancer Res; 2000 Aug; 6(8):3236-40. PubMed ID: 10955809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
